Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 1,201–1,300 of 1,676
Deane, C. S., Phillips, B. E., Smith, K., Steele, A. M., Libretto, T., Statton, S. A., Atherton, P. J., & Etheridge, T. (2020) · BMC Research Notes · doi:10.1186/s13104-020-05017-1 · Cited by 4
Athyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.958147 · Cited by 5
Diabetic Dyslipidemia and Risk of Cardiovascular Disease
Viljoen, A., Joshi, S., & Wierzbicki, A. S. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch43 · Cited by 6
Diagnosis, Evaluation, and Management of Severe Hypertriglyceridemia
Krishnamurthy, A., Homan, E. A., & Kim, S. M. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00758-9 · Cited by 5
“This study also failed to show a benefit in reducing vascular events despite increasing HDL-C and reducing LDL-C and triglycerides [19].”
Li, G., He, L., Bai, X., Chen, S., Dai, H., He, G., Yang, Y., Zhang, X., Cui, J., Li, X., et al. (2025) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2025.101689 · Cited by 8
Nelson, J. R. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000130 · Cited by 3
Lipoprotein(a) Lowering with Pelacarsen (TQJ230)
Sharma, K., Kattamuri, L. P. V., & Mukherjee, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x399029250923100015 · Cited by 6
Recent insights into the pathophysiology and implications for surgery in atherosclerosis
Liu, L., Wang, Z., Ma, L., & Wu, S. (2025) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-025-03655-9 · Cited by 4
“Unfortunately, their clinical efficacy has been limited, and some carry notable adverse effects [22, 54, 55].”
Xu, H., Li, B., Zhang, L., Ding, L., & Tian, P. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.11.021 · Cited by 3
Lowering of Lipoprotein(a) with Olpasiran
Amo-Tweneboah, C., & Kaur, G. (2026) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x428489260113103704 · Cited by 6
Evaluation and Management of Lipids and Lipoproteins in Children and Adolescents
Patel, A. J., & Patni, N. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.002 · Cited by 3
Wierzbicki, A. S. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2444986 · Cited by 10
“This original placebo-baseline study was revisited on a background of established statin therapy in the AIM-HIGH [76] and HPS-2/THRIVE [77] studies which showed that niacin therapy had no added benefit and an increased rate of adverse effects in patients managed on modern protocols [78].”
The Association of Niacin Use with Kidney Outcomes and Mortality
Takahashi, R., Bui, T.-A., Elali, I., Tran, D., Sumida, K., Thomas, F., Dukkipati, R. B., Shah, A. P., Rhee, C. M., Kovesdy, C. P., et al. (2025) · American Journal of Nephrology · doi:10.1159/000543098 · Cited by 4
“Regarding the previous reports, two major randomized controlled trials (RCTs) on niacin, the AIM-HIGH trial [23] and the HPS2-THRIVE trial [24], found no niacin effect on cardiovascular death or vascular events.”
Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels
Colantonio, L. D., & Bittner, V. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.01.004 · Cited by 5
Statin Alternatives: A Review of Over-the-Counter Lipid-Lowering Supplements
Danavi, J. V., Memon, S. B., & Phan, B. A. P. (2015) · Alternative and Complementary Therapies · doi:10.1089/act.2015.29018.jvd · Cited by 4
“56 have failed to demonstrate any parallel reduction in cardiovascular events or mortality when niacin is used as an adjunct to intense statin therapy.”
Narang, A., Mor‐Avi, V., Bhave, N. M., Tarroni, G., Corsi, C., Davidson, M. H., Lang, R. M., & Patel, A. R. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.006 · Cited by 3
Statins and Niacin: The End of Residual Risk Therapy?
Agouridis, A. P., & Mikhailidis, D. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_4 · Cited by 3
Janghorbani, M., Amini, M., & Aminorroaya, A. (2016) · The Review of Diabetic Studies · doi:10.1900/rds.2016.13.187 · Cited by 3
“Although increasing plasma HDLC levels have been suggested to reduce the risk of T2D [25], a recent trial showed that treatment with niacin, which raised HDLC, also raised blood glucose and T2D risk [26].”
BackgroundThe time for lipoprotein(a) based intervention has arrived: where will the light shine?
Nicholls, S. J., & Nelson, A. J. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.54 · Cited by 2
“Agents that have been demonstrated to reduce Lp(a) levels (niacin, oestrogen) do not reduce cardiovascular events (4,19).”
BackgroundMarinho, A. T., Batuca, J. R., Miranda, J. P., Caixas, U., Dias, C. G., Branco, T. L., Soto, K., Pinheiro, P. F., Bourbon, M., Marques, M. M., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105446 · Cited by 4
Cardiovascular Disease Epidemiology and Risk Factors: General Concepts
Toth, P. P. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-62632-7_1 · Cited by 6
Atherogenic Dyslipemia Working Group of the Spanish Society of Atherosclerosis and the European Expert Group (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.07.002 · Cited by 4
Atherogenic dyslipidaemia in type 2 diabetes mellitus: The PREDISAT study
Climent, E., Millán, J., Ascaso, J. F., Tembra, M. S., Morillas, C., Civeira, F., Bellón, J. M., Pedro‐Botet, J., & the Spanish Atherosclerosis Society Working Group on Atherogenic Dyslipidaemia (2023) · Lipids · doi:10.1002/lipd.12374 · Cited by 3
Feldman, J. M., Frishman, W. H., & Aronow, W. S. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000776 · Cited by 3
Trends and Prospects of Low-Density Lipoprotein Cholesterol in Stroke: A Bibliometric Analysis
Yang, B., Ma, X., Li, Y., Bian, G., Qiao, B., Lu, H., Wang, Z., Zhang, T., & Cheng, Y. (2024) · Cureus · doi:10.7759/cureus.69492 · Cited by 5
“Some efforts have been put into drug combinations to further reduce the risk of stroke on top of the LDL-C reduction achieved by statin therapy but failed [28,29].”
BackgroundChen, H., He, X., Fan, J., Mi, Y., & Li, F. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.11.004 · Cited by 3
High-Density Lipoprotein Infusions
Takata, K., Bartolo, B. A. D., & Nicholls, S. J. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.012 · Cited by 4
Werba, J. P., Vigo, L., Veglia, F., Marenzi, G., Tremoli, E., & Baldassarre, D. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1436 · Cited by 3
deGoma, E. M., Salavati, A., Shinohara, R. T., Saboury, B., Pollan, L. J., Schoen, M. A., Torigian, D. A., Mohler, E. R., Dunbar, R. L., Litt, H. I., et al. (2015) · Academic Radiology · doi:10.1016/j.acra.2014.12.015 · Cited by 3
The unresolved mystery of high-density lipoprotein: time for a paradigm shift?
Enkhmaa, B., Anuurad, E., & Berglund, L. (2016) · Translational research · doi:10.1016/j.trsl.2016.03.004 · Cited by 3
Rizos, E. C., & Elisaf, M. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1134462 · Cited by 3
Where to now in cardiovascular disease prevention
Najam, O., & Ray, K. K. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.036 · Cited by 3
Brinton, E. A., Triscari, J. M., Brudi, P., Chen, E., Johnson‐Levonas, A. O., Sisk, C. M., Ruck, R. A., MacLean, A. A., Maccubbin, D., & Mitchel, Y. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0282-8 · Cited by 4
Lloyd‐Jones, D. M. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4640 · Cited by 2
Pharmacogenomics of Blood Lipid Regulation
Legault, M., Tardif, J., & Dubé, M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0007 · Cited by 4
Saarinen, H. J., Husgafvel, S., Pohjantähti‐Maaroos, H., Wallenius, M., & Palomäki, A. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0340-7 · Cited by 5
The High Density Lipoprotein Cholesterol Hypothesis Revisited
Meiliana, A., Dewi, N. M., & Wijaya, A. (2018) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v10i2.465 · Cited by 3
“(1) Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and The Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials investigated the effect of niacin and niacin/laripoprant, respectively,…”
BackgroundOptimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk
Jones‐O’Connor, M., & Natarajan, P. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0741-4 · Cited by 3
Weir (2020) · The Journal of Family Practice · doi:10.12788/jfp.0068 · Cited by 3
Recognition and Management of Hypoglycemia
Shubrook (2020) · The Journal of Family Practice · doi:10.12788/jfp.0069 · Cited by 3
Lowenstern, A. M., Li, S., Návar, A. M., Virani, S. S., Roger, V. L., Robinson, J. G., Goldberg, A. C., Kampman, W., Peterson, E. D., & Wang, T. Y. (2021) · Clinical Cardiology · doi:10.1002/clc.23625 · Cited by 2
Changes of lipoprotein(a) levels with endogenous steroid hormones
Tessitore, E., Dobretz, K., Dhayat, N. A., Kern, I., Ponte, B., Pruijm, M. T., Ackermann, D., Estoppey, S., Burnier, M., Martin, P., et al. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13699 · Cited by 3
“11 On the other hand, both available PCSK-9 inhibitors have been shown to reduce Lp(a) levels by 20%– 35%, an effect that appears to reduce cardiovascular risk on top of LDL-C lowering.”
BackgroundResidual Cardiovascular Risk Factors in Dyslipidemia
Nguyen, V. S., Tran, X. T., Vo, T. D., & Le, Q. T. C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100046 · Cited by 3
Large-scale randomized evidence: Trials and meta-analyses of trials
Baigent, C., Peto, R., Gray, R. G., Staplin, N., Parish, S., & Collins, R. (2020) · doi:10.1093/med/9780198746690.003.0010 · Cited by 3
Devries, S. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35868-2.00026-8 · Cited by 3
Zhang, Y., & Wang, Y. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110021 · Cited by 5
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments
Polychronopoulos, G., Papagiannis, A., & Τζιόμαλος, Κ. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2174524 · Cited by 3
Niacin: Risk Benefits and Role in Treating Dyslipidemias
Guyton, J. R., Campbell, K. B., & Lakey, W. C. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_26 · Cited by 4
Diabetes and Atherogenic Dyslipidemia
Mooradian, A. D. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_38 · Cited by 4
Darabi, M., Zakiev, E., & Kontush, A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_18 · Cited by 3
Optimizing nicotinic acid delivery for durable antilipolysis and improved metabolic control
Kroon, T. (2016) · Epsilon Open Archive (Sveriges lantbruksuniversitet biblioteket (Swedish University of Agricultural Sciences)) · Cited by 3
Editorial commentary: A new era for preventive cardiology
Clarke, S. L. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.007 · Cited by 3
CSL112 and HDL function hypothesis – a never-ending wait
Zaman, M. A., Kalsoom, S., & Koran, W. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2378763 · Cited by 3
“Similarly, trials investigating niacin (HPS2-THRIVE, n = 25,673; AIM-HIGH, n = 3414) yielded negative results [26,27].”
Miyakoshi, T., Mutsuda, Y., Horiuchi, Y., et al. (2023) · Bioscience Reports · doi:10.1042/bsr20230393 · Cited by 2
“Another study showed that niacin could decrease low-density lipoprotein (LDL)-cholesterol levels and increase HDL-cholesterol levels, but they did not observe CVD risk reduction [3].”
Primary Hypoalphalipoproteinemia With Significant Premature Atherosclerosis
Moussa, S., Price, J., Frye, J. T., et al. (2024) · JACC Case Reports · doi:10.1016/j.jaccas.2024.102716 · Cited by 2
Clinical evidence for the use of NAD+ precursors to slow aging
Khatri, S., Abdellatif, M., & Sedej, S. (2025) · Geromedicine · doi:10.70401/geromedicine.2025.0008 · Cited by 4
Thanassoulis, G., Anand, S. S., Arsenault, B. J., Bainey, K. R., Bell, A., Brunham, L. R., Iatan, I., Koschinsky, M. L., Leiter, L. A., Mehta, S. R., et al. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.12.060 · Cited by 4
The Lipoprotein(a) Implementation Gap: Bridging Evidence and Clinical Practice
Yang, H. S., Yoon, S., & Hur, M. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm47152 · Cited by 3
Alcover, S., Ramos-Regalado, L., Muñoz‐García, N., Girón, G. O., Otero, S., López, S., Padró, T., Badimón, L., & Vilahur, G. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag187 · Cited by 4
“Although lower TG levels are associated with reduced ASCVD event risk, most CV outcomes trials of TG-lowering therapies (such as those involving niacin 11,12 and fi-brates 13,14 ) have failed to demonstrate significant reductions in CV endpoints, despite improvements in patients’ lipid profiles.”
Twenty-five years of statins: where do we go from here?
Gotto, A. M., & Moon, J. E. (2015) · Clinical Lipidology · doi:10.2217/clp.14.62 · Cited by 3
Improving the odds: ezetimibe and cardiovascular disease
Viljoen, A., & Wierzbicki, A. S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12613 · Cited by 2
Haynes, R., & Rahimi, K. (2016) · Heart · doi:10.1136/heartjnl-2015-308558 · Cited by 2
Houston, M. C., & Pizzorno, J. E. (2014) · PubMed · Cited by 2
Lipoprotein(a) and kidney diseases
Pyatchenkov, M. O., Rumyantsev, A. S., Владимирович, З. М., Sherbakov, E. V., & Belskykh, A. N. (2021) · Nephrology (Saint-Petersburg) · doi:10.36485/1561-6274-2021-25-1-31-46 · Cited by 3
Názara-Otero, C., Argüeso, R., Pedro‐Botet, J., Pintó, X., Millán, J., Seijo, M. P., Fernández, P. A., Ameneiros, M. E., del Alamo, A., Rodríguez, A., et al. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2022.11.002 · Cited by 2
Are we seeing the light at the end of the tunnel for high lipoprotein(a)? Lipoprotein(a)
Kayıkçıoğlu, M., Özkan, H. S., & Tokgözoğlu, L. S. (2023) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i3.21 · Cited by 2
Singh, N., Dove, E., & Bhatt, D. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00019-4 · Cited by 4
Luca, L. D., Temporelli, P. L., Gulizia, M. M., Gonzini, L., Ammaturo, T., Tedesco, L., Pede, S., Oliva, F. G., Gabrielli, D., Colivicchi, F., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.07.036 · Cited by 2
Quesada, J. A., Bertomeu‐González, V., Orozco‐Beltrán, D., Cordero, A., Gil-Guillén, V. F., López‐Pineda, A., Nouni-García, R., & Carratalá‐Munuera, C. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.07.006 · Cited by 5
Dyslipidemia in Metabolic Syndrome
Toh, S.-A. E. S., & Lee, M. H. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_58-1 · Cited by 4
Maravi, J. S. M., Leszczynski, E. C., Schwartz, C. S., Dev, P. K., Barber, J. L., Reasons, R. J., Pearce, R. W., McPhaul, M. J., Konrad, R. J., Robbins, J., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117587 · Cited by 4
Obeticholic acid's effect on HDL function in MASH varies by diabetic status
Kim, C., Tsai, T., López, R., McCullough, A. J., & Kasumov, T. (2024) · Lipids · doi:10.1002/lipd.12408 · Cited by 2
Dynamics of HDL-Cholesterol Following a Post-Myocardial Infarction Cardiac Rehabilitation Program
Bertolín‐Boronat, C., Merenciano-Gonzalez, H., Marcos‐Garcés, V., Mas, M. L. M., Alberola, J. I. C., Pérez-Solé, N., López, L., Argente, M. C. E., Reig, M. V., Benito, A. A., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25399 · Cited by 3
Management of Dyslipidemia in Chronic Kidney Disease
Vedamurthy, D., Sagheer, U., Patel, A., Singh, G., & Kalra, D. K. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00763-y · Cited by 3
“In a randomized trial of patients with vascular disease who were on statins, the addition of extended-release niacin-laropiprant did not significantly reduce the risk of major vascular events [81].”
Lipoproteins and Cardiovascular Disease Risk
Dhingra, R., & Vasan, R. S. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_4 · Cited by 2
Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs
Butters, J., Brown, A. D. H., Griffith, L., Kim, H., & Nicholls, S. J. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0231-6 · Cited by 2
Safety Considerations of Pharmacological Treatment
Kim, K., & Choi, S. H. (2021) · Stroke revisited · doi:10.1007/978-981-16-3923-4_17 · Cited by 2
Padala, S. K., Sidhu, M. S., & Boden, W. E. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_70 · Cited by 2
The year in cardiology 2014: coronary intervention
Iqbal, J., Serruys, P. W. J. C., Albuquerque, F. N., & Wijns, W. C. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu487 · Cited by 3
“disease to receive extended-release niacin and laropiprant or a matching placebo daily.(35) During a median follow-up period of 3.”
BackgroundUpdate on the Pharmacologic Agents for Dyslipidemia
Lee, S. (2015) · Journal of Korean Diabetes · doi:10.4093/jkd.2015.16.4.269 · Cited by 2
Prioritizing health outcomes in a limited world: writing lipid guidelines
Qureshi, N., Minhas, R., & Wierzbicki, A. S. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000170 · Cited by 3
Oral Administration of Sustained Release Niacin Inhibits Platelet Aggregation
Norgard, N. B., Bacon, N. R., & Agosti, M. (2016) · Current Clinical Pharmacology · doi:10.2174/1574884711666151214104315 · Cited by 2
Management of Moderate Hypertriglyceridemia in Childhood and Adolescence
Kavey, R.-E. W. (2016) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-016-0484-7 · Cited by 2
Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma
Suárez, S. R., Andreu, E. P., Grijalvo, O. M., & Morillo, J. S. G. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2015.07.004 · Cited by 2
Niacin: Time to Believe Outcomes Over Surrogate Outcomes
Krumholz, H. M. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.003094 · Cited by 2
Large Artery Occlusive Disease
Cole, J. W., & Stack, C. A. (2016) · InTech eBooks · doi:10.5772/65047 · Cited by 1
Pandey, A. S., BAJAJ, H. S., Garg, V., Pandey, A., & Verma, S. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000424 · Cited by 3
Effects of B Vitamins Overload on Plasma Insulin Level and Hydrogen Peroxide Generation in Rats
Sun, W. (2017) · The Chinese Journal of Physiology · doi:10.4077/cjp.2017.baf469 · Cited by 3
Harada, K., Kikuchi, R., Suzuki, S., Tanaka, A., Aoki, T., Iwakawa, N., Kojima, H., Hirayama, K., Mitsuda, T., Sumi, T., et al. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0670-3 · Cited by 2
Lipoprotein(a): the underutilized risk factor for cardiovascular disease
Khan, T. Z., Bornstein, S. R., & Barbir, M. (2019) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2019.11 · Cited by 2
Drugs that Affect Lipid Metabolism
Beckett, R. D., & Wilhite, A. L. (2015) · Side effects of drugs annual · doi:10.1016/bs.seda.2015.06.006 · Cited by 2
Nachar, W., Merlet, N., Maafi, F., Mihalache-Avram, T., Mecteau, M., Gélinas, D., Shi, Y., Brodeur, M. R., Alem, S., Blondeau, L., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.12.089 · Cited by 2
Pharmacological Management of Hyperlipidemia in Older Individuals
Tsu, L. V., Carroll, K. A., Kindler, K., & Early, N. K. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2021.284 · Cited by 2
Vitamins and minerals as nutraceuticals in cardiovascular diseases and other chronic diseases
Rai, R. H., Goyal, R. K., Singh, R. B., Handjiev, S., Singh, J., Handjieva‐Darlenska, T., & Smail, M. M. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819815-5.00037-9 · Cited by 6
Clinical strategies for reducing cholesterol levels
Lardinois, C. K., & Karr, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00027-4 · Cited by 2
Guimarães, B. C. D. S., Nogueira, D. N. E., Gonçalves, I. A., Raupp, G. C., Souza, B. C. D., Gonçalves, M. A., Cardoso, M. A., Carvalho, L. P. D., Gontijo, G. G. F., Miranda, I. P., et al. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n3-138 · Cited by 4
Pedro‐Botet, J., Barrios, V., Sánchez‐Margalet, V., Tamargo, J. L., Arrieta, F., Gámez, J. M., Gimeno-Orna, J. A., Escobar, C., Gómez‐Doblas, J. J., & Pérez, A. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.03.004 · Cited by 5
Naami, R., Miller, D. M., Al-Kindi, S. G., & Neeland, I. J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1084814 · Cited by 2
What is really new in triglyceride guidelines?
Hussain, A., Rifai, M. A., Hermel, M., Slipczuk, L. N., & Virani, S. S. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000802 · Cited by 2
“Both AIMHIGH (Atherothrombosis Intervention inMetabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes) [20] and HPS2-THRIVE (The Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events) [21] studies evaluated the efficacy of niacin among patients on statin ther…”
BackgroundBorja, M. S., Hammerson, B., Tang, C., Juarez-Serrano, L., Savinova, O. V., Harris, W. S., Oda, M. N., & Shearer, G. C. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296052 · Cited by 2
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.